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The 21st century saw a shift in the cholera burden from Asia to Africa. The risk factors for cholera outbreaks in
Africa are incompletely understood, and the traditional emphasis on providing safe drinking water and im-
proving sanitation and hygiene has proven remarkably insufﬁcient to contain outbreaks. Current killed whole-
cell oral cholera vaccines (OCVs) are safe and guarantee a high level of protection for several years. OCVs have
been licensed for >20 years, but their potential for preventing and control cholera outbreaks in Africa has not
been realized. Although each item in the long list of technical reasons why cholera vaccination campaigns have
been deferred is plausible, we believe that the biggest barrier is that populations affected by cholera outbreaks
are underprivileged and lack a strong political voice. The evaluation and use of OCVs as a tool for cholera
control will require a new, more compassionate, less risk-averse generation of decision makers.
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Cholera control programs have traditionally focused on
the provision of safe drinking water and improved sani-
tation. During the 20th century, when the major
cholera burden was in tropical Asia, the major break-
through in the treatment of cholera—oral rehydration
therapy—was conceived and evaluated in India and
Bangladesh [1–5]. Other cholera control strategies, in-
cluding health education, routine hand washing, and
improved food preparation, helped to contain major
outbreaks in Asia, as well as a large cholera outbreak in
South America, which started in 1991 in Peru and
quickly spread to many neighboring countries [6, 7]. In
the 1970s, Vibrio cholerae O1 spread to sub-Saharan
Africa, and the 21st century has been notable for hor-
rendous cholera outbreaks on the African continent [8].
In July 1994, an estimated 12 000 refugees in the Goma
refugee camp of the Democratic Republic of the Congo
died of cholera, despite the efforts of international or-
ganizations in setting up treatment centers [9]. More
recently, from August 2008 to July 2009, cholera spread
throughout Zimbabwe and spilled into neighboring
South Africa and Mozambique [10]. Aside from these
large outbreaks, endemic cholera is widespread, with
seasonal outbreaks documented in East, Central, South,
and West Africa. Control activities based on the provi-
sion of safe drinking water and improved sanitation
have failed to contain the spread of cholera, and out-
breaks are now common in sub-Saharan Africa. The
risk factors for cholera outbreaks in Africa are incom-
pletely understood, and it remains challenging to
predict outbreaks reliably [11–15].
Cholera vaccines have evolved from injectable vac-
cines with side effects and questionable protective efﬁ-
cacy to the current state-of-the-art killed whole-cell
oral cholera vaccines (OCVs), which are safe and guar-
antee a high level of protection for several years. OCVs
have been licensed and prequaliﬁed for purchase by
United Nations agencies since the early 1990s, but they
have been mostly ignored for public health purposes
and are marketed for afﬂuent tourists who perceive
themselves at risk for cholera. The purpose of this
article is to review the potential and the obstacles for
the use of cholera vaccines on the African continent.
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CHOLERAVACCINE TYPES
Up to the 1990s, the only available cholera vaccines were made
from phenol-killed whole cells of V. cholerae O1 organisms and
administered by injection as 2 doses given 2 weeks apart. The
vaccine offered around 50% protection for a short duration, was
associated with painful local inﬂammatory reactions, and is no
longer recommended for use [16]. Parenteral cholera vaccines
have been replaced by orally administered vaccines: killed whole-
cell vaccines and genetically modiﬁed live attenuated vaccines.
Killed Whole-Cell OCVs
The ﬁrst internationally licensed OCV, Dukoral (Crucell, the
Netherlands), contains several V. cholerae O1 strains and the
recombinant cholera toxin B subunit (WC/rBS). A trial con-
ducted in 90 000 people aged >2 years in Matlab, Bangladesh,
between 1985 and 1989 found 85% protection in the ﬁrst 6
months after vaccination and 50% protection over the 3-year
follow-up period [17]. A reanalysis of this trial in 2005 discov-
ered that a high level of protection against cholera was con-
ferred by the vaccine, even among people who had not been
vaccinated but lived in communities with high vaccine coverage
[18]. The WC/rBS vaccine has been assessed in several African
settings. The effectiveness of the WC/rBS vaccine was evaluated
following a large mass vaccination campaign in Beira, Mozam-
bique, in 2004 [19]. Using a case-control approach, the investi-
gators found that the vaccine afforded about 80% protection in
the year after the vaccination campaign. The ﬁndings from Mo-
zambique are of particular importance for 2 reasons. First, the
circulating V. cholerae strains in the setting were genetic vari-
ants of the El Tor strain, with a classic V. cholerae toxin cassette
[20]. Second, the prevalence of human immunodeﬁciency virus
(HIV) infection in Beira was very high, as indicated by the
20%–30% prevalence among women of child-bearing age [21].
The results from the Mozambique study showed that the WC/
rBS vaccine protected against this new variant V. cholerae
strain, which is spreading throughout Africa, even in environ-
ments with a high HIV prevalence. Subsequently, the feasibility
of mass vaccination campaigns was evaluated in Aceh, Indone-
sia, following the Asian tsunami, in 2004, and in a refugee
camp in Darfur, western Sudan. These studies demonstrated
that mass vaccination campaigns with the WC/rBS vaccine can
be successfully completed in complex emergencies [22]. In the
beginning of 2009, a mass vaccination campaign with the WC/
rBS vaccine, conducted in Zanzibar, found protection similar
to that in the earlier study in Mozambique. The study in Zanzi-
bar suggested that, in addition to direct protection of vaccinat-
ed individuals, the vaccine also afforded herd immunity to
nonvaccinated people, similar to the Matlab trial. A distinct
disadvantage of the WC/rBS vaccine is its high price, which is
due at least in part to the production cost of the recombinant B
subunit and the need for a buffer.
The next generation of killed whole-cell OCV no longer con-
tains WC/rBS. The ﬁrst of these new vaccines was produced
in Vietnam, following a technology transfer from Sweden to
VaBiotech, Vietnam [23]. The Vietnamese vaccine producers
replaced several of the original V. cholerae strains and added
the O139 strain, resulting in a bivalent vaccine containing
V. cholerae O1 and O139. Field testing of the Vietnamese
vaccine protected 66% of recipients for 10 months after vacci-
nation [24]. The vaccine was licensed in Vietnam and widely
used in the country’s public health program to control cholera
—the only country to create such a program. The vaccine was
not prequaliﬁed for purchase by United Nations agencies.
During the last decade, the Vietnamese vaccine production
protocol was slightly revised, and its technology was transferred
to an Indian vaccine producer (Shantha Biotechnics, Hydera-
bad, India). A large, 3-year ﬁeld trial of this Indian vaccine,
Shanchol, in Kolkata, India, found that the vaccine was safe and
afforded 66% protection [25]. Shanchol received prequaliﬁca-
tion for purchase by United Nations agencies in September
2011. The second-generation killed whole-cell OCVs have 2 ad-
vantages over the ﬁrst-generation WC/rBS vaccine: affordabili-
ty and ease of administration. Shanchol is sold for $1.85 per
dose, while Dukoral is sold to the public sector for $4.70 or
more per dose [26] (Table 1).
The Chinese vaccine producer Shanghai United Cell Bio-
technology also produces a WC/rBS vaccine, OraVacs, which
has been licensed in China and the Philippines [30]. Reports on
the safety and efﬁcacy of this vaccine have yet to be published
in peer-reviewed international journals. In contrast to the prod-
ucts listed above, OraVacs does not have to be reconstituted
because it is formulated as an enteric coated capsule. The
vaccine has been made available to the Chinese government for
emergencies, such as the earthquake that affected eastern China
in May 2008 [31]. Considering the increasingly prominent role
of China in Africa, a broader use of this vaccine in African set-
tings could become possible. Evaluation of the safety and pro-
tection afforded by OraVacs according to international good
clinical practices standards is highly desirable prior to wide-
spread use.
Live Attenuated OCV
In addition to the killed whole-cell OCVs, a genetically modi-
ﬁed live attenuated OCV, CVD 103-HgR, has been licensed.
The vaccine was safe and afforded promising protection in
North American volunteers [32] but was likely underpowered
to show protection during any of the 4 years of follow–up in a
large trial in Jakarta, Indonesia [33]. The vaccine, Orachol or
Mutachol, was used in a mass vaccination campaign in Micro-
nesia, where a retrospective case-control study estimated 79%
protection [34]. The vaccine is administered as a single dose
with a buffer. Production of the vaccine was stopped by the
producer (Crucell, Switzerland), most likely because of business
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considerations. PaxVax, of Menlo Park, California, is working
toward the reintroduction of an improved, new-generation
version of CVD 103-HgR [35].
In addition to the licensed OCVs mentioned above, there are
several promising vaccine candidates in development. Genetic
modiﬁcation of V. cholerae O1 El Tor strains isolated in Peru
has resulted in the vaccine candidate Peru 15. Current phase 2
studies suggest that it has a promising safety and immunoge-
nicity proﬁle [36]. Other candidates, such as V. cholerae
638, VA 1.3, and IEM 108, are currently undergoing clinical
evaluation [37–40].
USE OF VACCINES IN CHOLERA EPIDEMICS
AND CHOLERA-ENDEMIC SETTINGS IN
AFRICA
In general cholera comes in two varieties in Africa: (1) an
endemic distribution, with seasonal variations and peaks every
1–3 years that result in a steady ﬂow of hospital admissions;
and (2) an acute-onset epidemic distribution, which may affect
hundreds of thousands of individuals at the same time and
overwhelm existing healthcare systems. The latter distribution
tends to occur in areas with infrastructure breakdown, such as
Haiti and Zimbabwe, and often where cholera has been
absent for many years, resulting in a large pool of susceptible
individuals.
In settings where cholera is endemic, improvements
in infrastructure—speciﬁcally, drinking water supply and
sanitation—are the long-term solutions, but in the medium
term, vaccines could reduce the cholera burden. Endemic
cholera tends to be highly heterogeneous in distribution, sparing
certain communities. Ideally, vaccination campaigns would
target geographically well-deﬁned high-risk areas. In practice, it
is very difﬁcult to identify such hot spots. Furthermore, target-
ing high-risk groups and withholding the vaccine from other
population groups can result in political tension. Thus, it is
more promising to vaccinate the affected areas, with a wide
safety margin, or to vaccinate the whole city.
In areas of cholera epidemics, the priority is to reduce cholera-
related deaths, and the focus of outbreak response is to ensure
proper case management. At the extreme end of the spectrum
are outbreaks such as that in Zimbabwe, during 2008–2009,
which resulted in 98 591 cases and 4288 deaths [10]. In the Haiti
outbreak, which began in 2010, 515 699 cases have been report-
ed, with 6942 deaths by November 2011 [41]. In both instances,
a combination of critical factors provided the ideal conditions for
continued propagation of the outbreak, including the prolonged
deterioration of infrastructure. Both areas had large cholera-
naive populations, a health system unprepared to respond to the
outbreak, and the introduction of a highly infectious strain of V.
cholerae. The intense effort in providing proper treatment and
the classic prevention strategies—provision of safe drinking
Table 1. Comparison of 2 Currently Licensed Oral Cholera Vaccines (OCVs)
Characteristic Whole-Cell rBS OCV Killed Whole-Cell OCV
Trade name Dukoral Shanchol
Composition [1, 2] • V. choleraeO1 Inaba classic strain,
heat-inactivated vibrios
• V. choleraeO1 Inaba El Tor strain, formalin-
inactivated vibrios
• V. choleraeO1 Ogawa classic strain, formalin-
inactivated vibrios
• V. choleraeO1 Ogawa classic strain,
heat-inactivated vibrios
• Recombinant V. cholerae toxin B subunit 1 mg
• V. choleraeO1 Inaba classic strain Cairo 48,
heat-inactivated vibrios
• V. choleraeO1 Inaba El Tor strain Phil 6973,
formalin-inactivated vibrios
• V. choleraeO1 Ogawa classic strain Cairo 50,
formalin-inactivated vibrios
• V. choleraeO1 Ogawa classic strain Cairo 50,
heat-inactivated vibrios
• V. choleraeO139 strain 4260B, heat-inactivated
vibrios
Producer Crucell, a subsidiary of Johnson and Johnson Shanta Biotechnics, a subsidiary of the Sanofi group
Buffer requirement Yes, to stabilize the B subunit No
Efficacy [3] 60% efficacy over 2 y 67% vaccine efficacy over 3 y
Price [3] $4.70/dose (discounted for public health use/
emergencies)
$1.85/dose
Dosing • 2-dose requirement for individuals aged ≥5 y
• 3 doses for children aged <5 y
2-dose requirement
Minimum age ≥2 y ≥1 y
Administration
during pregnancy
No data; thus, not recommended No data; thus, not recommended
WHO prequalified Yes Yes
Data are from [27, 28, 29].
Abbreviations: rBS, recombinant cholera toxin B subunit; V. cholerae, Vibrio cholerae; WHO, World Health Organization.
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water and improved sanitation and hygiene—were insufﬁcient to
avoid a high increase in mortality in these countries. It may have
been possible to contain outbreaks through a reactive mass vacci-
nation campaign. We calculated that, for a large outbreak like the
one in Zimbabwe, 40% of cases and deaths could be prevented if
the risk for a large outbreak is recognized early and a vaccination
campaign is executed with reasonable speed [42]. Clear advan-
tages of reactive vaccination campaigns are a highly motivated
population and the assurance of political support, which are
likely to result in high vaccine coverage. In October 2009, the
Strategic Advisory Group of Experts advised the World Health
Organization to consider reactive vaccination campaigns in re-
sponse to large cholera outbreaks [43].
OCVs have been considered useful tools for avoiding out-
breaks in complex emergencies. The cholera outbreak in Goma,
in 1994, showed the catastrophic consequences of cholera out-
breaks in such contexts. But not all areas of disaster are affected
by cholera. Models to predict cholera outbreaks tend to be based
on climate, the presence of endemic cholera cases, and poor
water supply and sanitation and can be quite sensitive yet not
speciﬁc [13, 15, 44]. Frequently, one critical variable, the size of
the susceptible population, is unknown. Individuals in many at-
risk locations would have to be preemptively vaccinated to prevent
a limited number of actual outbreaks. Mass vaccination campaigns
require large amounts of resources that, consequently, will not be
available for other healthcare services. The value of preventive
mass vaccination campaigns will be difﬁcult to predict until sensi-
tive and speciﬁc tools for risk assessment have been developed.
STOCKPILING CHOLERAVACCINES
To contain large outbreaks of cholera, a large number of
immediately available OCV doses will be required. Scaling up
production takes 1–3 years and depends on the commitment of
prospective buyers. The international community has long
delayed putting in place a mechanism to ensure the availability
of cholera vaccines when needed. The epidemiology of cholera
is not unique: cases of meningococcal meningitis and yellow
fever also tend to occur as epidemics. For the latter diseases, the
international donor community has established large stockpiles
of vaccines [35]. Both stockpiles make use of revolving vaccine
doses managed by 4 partners, UNICEF (the United Nations
Children’s Fund), Médecins Sans Frontières, the International
Federation of Red Cross and Red Crescent Societies, and the
World Health Organization, through an international coordi-
nating group. When a country requests vaccines, the coordinat-
ing group promises to come to a decision within 48 hours and
to deliver the vaccine within a maximum period of 7 days. The
decision whether to approve a request is based on predeter-
mined criteria: epidemiological evidence for an outbreak,
which includes laboratory conﬁrmation; availability of an
action plan for mass vaccination; and adequate storage
conditions. There is an urgent need for a similar cholera
vaccine stockpile [45]. Much can be learned from the experi-
ence of running the meningitis vaccine and yellow fever
vaccine stockpiles, which have been in existence since 1997 and
2001, respectively. In addition to the similarities between me-
ningococcal disease, yellow fever, and cholera, there are differ-
ences, not least in the risk groups. Considering the vulnerability
of the populations at risk for cholera, there is a need to ensure
equitable access to vaccines and to minimize the potential for
implementing organizations to abuse the process. Major chal-
lenges for the meningitis and yellow fever vaccine stockpiles
involve how to ensure continued ﬁnancing for the stockpile
program and how to use vaccines with limited remaining shelf
life if no requests for them have been made during the year.
Cholera vaccines that have not been used in outbreaks and ap-
proach the end of their shelf-life could be used for disease
control in cholera-endemic settings.
BARRIERS TO USING CHOLERAVACCINES IN
AFRICA: LOGISTICS AND OTHER
CONSIDERATIONS
The single biggest barrier to the use of cholera vaccines could be
the ﬁnancial investment required to vaccinate millions of people.
But cost has not prevented widespread use of other vaccines.
Large mass vaccination campaigns are major logistical undertak-
ings, a further barrier against the widespread use of cholera vac-
cines. The success of a mass vaccination campaign is measured in
terms of the vaccine coverage achieved by the vaccination team.
Cholera mass vaccination campaigns cannot rely on a preexisting
infrastructure because in most cases it is the very absence of an
infrastructure that has resulted in an outbreak. While vaccination
campaigns in cholera-endemic settings are challenging, reactive
vaccination campaigns are a daunting task even for hardened lo-
gisticians. The healthcare system is already stretched, and the
most experienced staff who, under normal circumstances, would
work on a vaccination campaign are either treating cholera cases
or have been affected by the disease. A major reason why cholera
vaccines have found so little public health use are these technical
barriers [46]. In the past, the World Health Organization has
failed to support or has advised against the use of cholera vac-
cines, citing a catalogue of technical arguments [46, 47]. It seems
likely that a list of these arguments will be rolled out each time a
mass vaccination campaign is considered. We believe that a
closer look at these technical barriers of a reactive mass oral
cholera vaccination campaign is necessary.
Water Provision and Cholera Treatment Measures Take Priority
Over Vaccination
There should never be a competition between mass vaccina-
tions and safe drinking water and sound sanitation. Experience
in recent decades has amply demonstrated that activities to
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procure safe drinking water and improve sanitation are insufﬁ-
cient to prevent cholera on the African continent. Cholera vac-
cinations should by no means replace safe drinking water and
sound sanitation. Instead, vaccination campaigns must be in-
cluded among efforts to improve the supply of safe drinking
water and sound sanitation.
Convincing Modeling Data on the Beneﬁt of Vaccination
Campaigns Are Nonexistent
Models have to make assumptions. To predict the beneﬁt of
mass vaccination campaigns, it is essential to know not only
the peak but also the duration of an outbreak, which is highly
variable. From our knowledge, it is impossible to predict
(during the early days of an outbreak) the characteristics of the
entire epidemic curve and, thus, the overall number of cases
and deaths preventable by early mass vaccination campaigns.
Estimating the beneﬁt of a mass vaccination campaign is only
possible with hindsight.
Mobile Populations Cannot Be Relied on to Take 2 Doses
The uptake of the second dose of cholera vaccine is likely to be
determined by the ease of vaccine access and the level of moti-
vation of the participant. If the participants understand that 2
vaccine doses are required to confer immunity and know that
they are at high risk for cholera, a high uptake of the second
dose is quite likely. In a recent mass vaccination campaign in
Zanzibar, 86% of the campaign participants (23 921/27 678)
who received the ﬁrst dose also received the second dose. The
corresponding percentage in Mozambique was 78% [19].
Immunity Is Not Generated Until 1 Week After the Second Dose
This argument is frequently followed by the suggestion to wait
until a single dose becomes available. A single dose prevents
signiﬁcantly more cases during very short cholera outbreaks,
for which the use of mass vaccination campaigns may be ques-
tionable in the ﬁrst place. During extended large outbreaks,
such as those in Zimbabwe and Haiti, a delay in full immunity
by 2 weeks would make an insigniﬁcant difference in the
number of cases prevented [42]. Research is ongoing to under-
stand the short-term effectiveness of a single dose of Shanchol.
Logistics Are Challenging in Settings of Inadequate
Infrastructure and Human Resources
The logistical challenges of mounting a cholera vaccination
campaign can be daunting. But the logistical challenges associ-
ated with a reactive inﬂuenza mass vaccination campaign will
also be of an enormous scale. Yet nobody has suggested with-
holding mass inﬂuenza vaccination campaigns because of logis-
tical challenges. The difference between cholera and inﬂuenza
vaccination campaigns is not the scale of the logistical challenge
but the absence of vigorous advocacy for populations at risk for
cholera.
Cold-Chain Requirements Cannot Be Met
There is no absolute requirement for the refrigeration of OCV
containing killed whole-cell bacteria. Stability tests with Shan-
chol have indicated that the vaccine can remain outside the
cold chain at temperatures up to 37°C for 21 days, although
this information is not included in the label [35]. It should
be noted that other vaccines, including the universally used
vaccines in the World Health Organization’s Expanded Pro-
gramme on Immunization, require refrigeration.
Vaccine Is Too Bulky for Transport
The storage space for 100 000 single doses of cholera vaccine is
9 m3, but the storage requirement is much smaller for multiple-
dose vials [35]. The provision of the vaccine via multiple-dose
vials will reduce the storage requirements considerably.
Clean Water Is Needed for the Buffer
The second-generation OCVs, such as Shanchol or the Chinese
OraVacs vaccine, do not require the use of a buffer.
Public Response to the Vaccination Campaign Cannot Be
Predicted During Civil Unrest
In every community, a small fraction of the population refuses
to participate in mass campaigns, irrespective of the interven-
tion. In Mozambique and Zanzibar, people residing outside the
targeted areas travelled to vaccination centers, suggesting that,
at the other end of spectrum, there is a population of highly
motivated individuals who will actively seek to be vaccinated.
The shape of the resulting response curve depends on the sensi-
tization campaign preceding the vaccination campaign and on
the perception of risk by the population. If the target popula-
tion is adequately educated about the characteristics of the
vaccine and each individual knows ≥1 person with cholera, a
very high coverage is virtually assured.
Vaccination Campaigns Are Not Cost-effective
Last, concerns about the cost-effectiveness of cholera vaccina-
tion campaigns must be addressed. There is a lack of data on
the economic beneﬁts of OCVs in severe outbreaks, although
their cost-effectiveness in cholera-endemic settings has been
demonstrated [48, 49]. A more recent analysis concluded that
the use of OCVs is very cost-effective in Africa, regardless of
whether herd immunity was taken into account [26]. It is im-
portant to keep in mind that the damage to the local economy
caused by large cholera outbreaks is compounded by a negative
impact on tourism and food, especially seafood exports.
This larger economic damage tends to be overlooked in cost-
effectiveness studies. Most importantly, we believe that anyone
who has lived through the agonizing indignities of a cholera
attack, especially one that occurred during a cholera outbreak,
would without hesitation dismiss the argument that cholera
vaccines may not be cost-effective.
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CONCLUSION
The continent most affected by cholera is no longer Asia but
Africa and V. cholerae has adapted to the new environment.
A variant strain of V. cholerae O1, El Tor, has successfully
spread through the African continent, while control methods
have remained the same. The results have been catastrophic, as
illustrated by recent massive cholera outbreaks. Yet the interna-
tional donor community has steadfastly refused to purchase
and deploy safe and effective OCVs, even in the face of thou-
sands of deaths in very large outbreaks. Each item in the long
list of technical reasons why mass vaccination campaigns have
been deferred is plausible—not for one second do we want to
belittle the massive challenges of mass vaccination campaigns.
But if a catastrophic situation similar to a large cholera out-
break occurred among more-privileged groups, a much more
aggressive response from the international community would
be likely. The main reason why cholera vaccines have not been
used in Africa and countries like Haiti 20 years after they have
been licensed and shown to be effective is that people affected
by cholera outbreaks are underprivileged, even by the standards
of impoverished populations. The evaluation and use of OCVs
as a tool for cholera control will require a new, more compas-
sionate, less risk-averse generation of decision makers.
Note
Potential conﬂicts of interest. All authors: No reported conﬂicts.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conﬂicts of Interest. Conﬂicts that the editors consider relevant to the
content of the manuscript have been disclosed.
References
1. Bhan MK, Mahalanabis D, Fontaine O, Pierce NF. Clinical trials of im-
proved oral rehydration salt formulations: a review. Bull World Health
Organ 1994; 72:945–55.
2. Bhattacharya SK. History of development of oral rehydration therapy.
Indian J Public Health 1994; 38:39–43.
3. Watten RH, Morgan FM, Yachai Na S, Vanikiati B, Phillips RA. Water
and electrolyte studies in cholera. J Clin Invest 1959; 38:1879–89.
4. Carpenter CC, Mitra PP, Sack RB, Dans PE, Wells SA, Chaudhuri RN.
Clinical evaluation of ﬂuid requirements in asiatic cholera. Lancet
1965; 1:726–7.
5. Cash RA, Toha KM, Nalin DR, Huq Z, Phillips RA. Acetate in the cor-
rection of acidosis secondary to diarrhoea. Lancet 1969; 2:302–3.
6. Seas C, Miranda J, Gil AI, et al. New insights on the emergence of
cholera in Latin America during 1991: the Peruvian experience. Am J
Trop Med Hyg 2000; 62:513–7.
7. Sepulveda J, Valdespino JL, Garcia-Garcia L. Cholera in Mexico: the
paradoxical beneﬁts of the last pandemic. Int J Infect Dis 2006;
10:4–13.
8. Goodgame RW, Greenough WB. Cholera in Africa: a message for the
West. Ann Intern Med 1975; 82:101–6.
9. Public health impact of Rwandan refugee crisis: what happened in
Goma, Zaire, in July, 1994? Goma Epidemiology Group. Lancet 1995;
345:339–44.
10. WHO. Outbreak news cholera, Zimbabwe. Weekly Epidemiological
Record 2009; 84:517–32.
11. Emch M, Feldacker C, Yunus M, et al. Local environmental predictors
of cholera in Bangladesh and Vietnam. Am J Trop Med Hyg 2008;
78:823–32.
12. Lipp EK, Huq A, Colwell RR. Effects of global climate on infectious
disease: the cholera model. Clin Microbiol Rev 2002; 15:757–70.
13. Matsuda F, Ishimura S, Wagatsuma Y, et al. Prediction of epidemic
cholera due to Vibrio cholerae O1 in children younger than 10
years using climate data in Bangladesh. Epidemiol Infect 2008;
136:73–9.
14. Sack RB, Siddique AK, Longini IM Jr, et al. A 4-year study of the epide-
miology of Vibrio cholerae in four rural areas of Bangladesh. J Infect
Dis 2003; 187:96–101.
15. Reyburn R, Kim DR, Emch M, Khatib A, von Seidlein L, Ali M.
Climate variability and the outbreaks of cholera in Zanzibar, East
Africa: a time series analysis. Am J Trop Med Hyg 2011; 84:
862–9.
16. Mosley WH, Aziz KM, Mizanur Rahman AS, Alauddin Chowdhury
AK, Ahmed A, Fahimuddin M. Report of the 1966–67 cholera
vaccine trial in rural East Pakistan. Bull World Health Organ 1972;
47:229–38.
17. Clemens JD, Sack DA, Harris JR, et al. Field trial of oral cholera vac-
cines in Bangladesh: results from three-year follow-up. Lancet 1990;
335:270–3.
18. Ali M, Emch M, von Seidlein L, et al. Herd immunity conferred by
killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 2005;
366:44–9.
19. Lucas ME, Deen JL, von Seidlein L, et al. Effectiveness of mass oral
cholera vaccination in Beira, Mozambique. N Engl J Med 2005; 352:
757–67.
20. Faruque SM, Tam VC, Chowdhury N, et al. Genomic analysis of the
Mozambique strain of Vibrio cholerae O1 reveals the origin of El Tor
strains carrying classical CTX prophage. Proc Natl Acad Sci U S A
2007; 104:5151–6.
21. WHO. Mozambique, summary country proﬁle for HIV/AIDS treat-
ment scale-up 2004: the 3 by 5 Initiative. http://www.who.int/3by5/
support/june2005_moz.pdf. Posted June 2005, last accessed 17 May
2013.
22. Chaignat CL, Monti V, Soepardi J, et al. Cholera in disasters: do vac-
cines prompt new hopes? Expert Rev Vaccines 2008; 7:431–5.
23. Lopez-Gigosos RM, Plaza E, Diez-Diaz RM, Calvo MJ. Vaccination
strategies to combat an infectious globe: oral cholera vaccines. J Glob
Infect Dis 2011; 3:56–62.
24. Trach DD, Clemens JD, Ke NT, et al. Field trial of a locally produced,
killed, oral cholera vaccine in Vietnam. Lancet 1997; 349:231–5.
25. Sur D, Kanungo S, Sah B, et al. Efﬁcacy of a low-cost, inactivated
whole-cell oral cholera vaccine: results from 3 years of follow-up of a
randomized, controlled trial. PLoS Negl Trop Dis 2011; 5:e1289.
26. Maskery B. http://www.ivi.int/publication/IVI_Global_cholera_case.
pdf 2011.
27. Dukoral Application for Reclassiﬁcation. Jul 11 1 Submission for Reclassi-
ﬁcation of Dukoral. http://www.medsafe.govt.nz/profs/class/agen46Vibrio-
Cholera.pdf. Accessed 17 May 2013.
28. WHO Immunization Standards: Vaccine Quality. http://www.who.int/
immunization_standards/vaccine_quality/en/. Accessed 17 May 2013.
29. Maskery B, Levin A, DeRoeck D, Kim YE, Ali M, Burgess C, Lopez AL,
Wierzba T, Shin S, Clemens J. Cholera Vaccines: An Investment
Case http://www.ivi.int/publication/IVI_Global_cholera_case.pdf. Ac-
cessed 17 May 2013.
30. Shanghai United Cell Biotechnology. OraVacs. http://english.united
biotech.com.cn/en/EnProduct-OCV-general.asp. Accessed 17 May 2013.
31. Frew SE, Liu VY, Singer PA. A business plan to help the ‘global South’
in its ﬁght against neglected diseases. Health Aff (Millwood) 2009;
28:1760–73.
32. Levine MM, Kaper JB, Herrington D, et al. Safety, immunogenicity,
and efﬁcacy of recombinant live oral cholera vaccines, CVD 103 and
CVD 103-HgR. Lancet 1988; 2:467–70.
Value of and Challenges for Cholera Vaccines in Africa • JID 2013:208 (Suppl 1) • S13
33. Richie EE, Punjabi NH, Sidharta YY, et al. Efﬁcacy trial of single-dose
live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a
cholera-endemic area. Vaccine 2000; 18:2399–410.
34. Calain P, Chaine JP, Johnson E, et al. Can oral cholera vaccination play a
role in controlling a cholera outbreak? Vaccine 2004; 22:2444–51.
35. WHO. WHO Consultation on oral cholera vaccine (OCV) stockpile
strategic framework: potential objectives and possible policy options.
Geneva: WHO, 2011.
36. Chowdhury MI, Sheikh A, Qadri F. Development of Peru-15 (Cholera-
Garde), a live-attenuated oral cholera vaccine: 1991–2009. Expert Rev
Vaccines 2009; 8:1643–52.
37. Garcia L, Jidy MD, Garcia H, et al. The vaccine candidate Vibrio chol-
erae 638 is protective against cholera in healthy volunteers. Infect
Immun 2005; 73:3018–24.
38. Mahalanabis D, Ramamurthy T, Nair GB, et al. Randomized placebo
controlled human volunteer trial of a live oral cholera vaccine VA1.3
for safety and immune response. Vaccine 2009; 27:4850–6.
39. Thungapathra M, Sharma C, Gupta N, et al. Construction of a recombi-
nant live oral vaccine from a non-toxigenic strain of Vibrio cholerae O1
serotype inaba biotype E1 Tor and assessment of its reactogenicity and
immunogenicity in the rabbit model. Immunol Lett 1999; 68:219–27.
40. Liang W, Wang S, Yu F, et al. Construction and evaluation of a safe,
live, oral Vibrio cholerae vaccine candidate, IEM108. Infect Immun
2003; 71:5498–504.
41. WHO Response in Haiti Health Cluster Bulletin #30 Cholera and Post-
Eartchquake Response in Haiti. http://new.paho.org/hai/index.php?
option=com_content&view=article&id=7104%3Ahealth-cluster-bulletin-
&Itemid=255&lang=en#30-cholera-and-post-eartchquake-response-
in-haiti&catid=687:hai.-health-cluster-reports&Itemid=255. Accessed
17 May 2013.
42. Reyburn R, Deen JL, Grais RF, et al. The case for reactive mass oral
cholera vaccinations. PLoS Negl Trop Dis 2011; 5:e952.
43. WHO. Meeting of the Strategic Advisory Group of Experts on immuni-
zation, October 2009—conclusions and recommendations. Wkly Epi-
demiol Rec 2009; 50:526–8.
44. Constantin de Magny G, Murtugudde R, Sapiano MR, et al. Environ-
mental signatures associated with cholera epidemics. Proc Natl Acad
Sci U S A 2008; 105:17676–81.
45. Ramsay S. WHO Technical Working Group on creation of an oral
cholera vaccine stockpile. Geneva: WHO, 2012. http://www.who.int/
cholera/publications/oral_cholera_vaccine/en/index.html. Accessed 17
May 2013.
46. Date KA, Vicari A, Hyde TB, et al. Considerations for oral cholera
vaccine use during outbreak after earthquake in Haiti, 2010–2011.
Emerg Infect Dis 2011; 17:2105–12.
47. Chaignat CL, Monti V. Use of oral cholera vaccine in complex emer-
gencies: what next? Summary report of an expert meeting and recom-
mendations of WHO. J Health Popul Nutr 2007; 25:244–61.
48. Jeuland M, Cook J, Poulos C, Clemens J, Whittington D. Cost-
effectiveness of new-generation oral cholera vaccines: a multisite analy-
sis. Value Health 2009; 12:899–908.
49. Jeuland M, Whittington D. Cost-beneﬁt comparisons of investments in
improved water supply and cholera vaccination programs. Vaccine
2009; 27:3109–20.
S14 • JID 2013:208 (Suppl 1) • von Seidlein et al
